Hyperfine (HYPR) Earnings Date & Reports

Key Takeaways

• Hyperfine reported record third quarter 2026 revenue of $6.0 million, up 73% year over year and 53% sequentially.
• Net loss narrowed to $0.06 per share, beating the consensus estimate of a $0.08 loss.
• Gross margin reached a record 56.7%, marking the company's fifth consecutive quarter above 50%.
• The company sold 14 Swoop portable MRI (magnetic resonance imaging) systems, up 75% from 8 units a year earlier.
• Net cash burn fell 29% sequentially to $5.6 million, and for the first time quarterly revenue exceeded net cash burn.
• Full-year 2026 revenue guidance was reaffirmed at $20 million to $22 million.
• For more on Hyperfine's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for deeper, data-driven coverage.
• Discover timely trade ideas and market opportunities by exploring Trending AI Robots.

Earnings Context and Why It Matters

Hyperfine, the health technology company behind the first FDA-cleared AI-powered portable brain MRI system, is still in a high-growth, pre-profitability phase. This report matters because it tests whether the company can scale revenue while narrowing losses and extending its cash runway. Coming off 45% year-over-year revenue growth in the second quarter, investors were watching whether commercial momentum in U.S. hospitals, neurology offices, and international markets could continue. The third quarter also carried significance beyond the top line, as progress on gross margin and cash burn signals how efficiently Hyperfine's "land-and-expand" commercial model is maturing.

Reported Results

Hyperfine delivered its strongest quarterly results in company history for the period ended September 30, 2026. Revenue was a record $6.0 million, an increase of 73% from $3.4 million in the third quarter of 2025 and up 53% from the second quarter of 2026. The company sold 14 systems, a 75% increase from 8 units in the prior-year period, with growth spread across all three commercial verticals: U.S. hospital, U.S. office, and international.

Gross profit reached a record $3.4 million, up 83% year over year, while gross margin expanded to a record 56.7% from 53.8% a year earlier. Operating loss narrowed to $7.3 million, the company's narrowest quarterly operating loss and a 19% improvement year over year. Net loss was $6.0 million, or $0.06 per share, compared with a net loss of $11.0 million, or $0.14 per share, in the same period last year. The per-share result beat the consensus estimate of a $0.08 loss by $0.02. Net cash burn declined 29% sequentially to $5.6 million, and quarterly revenue exceeded net cash burn for the first time. Management reaffirmed full-year 2026 revenue guidance of $20 million to $22 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, helping investors focus their research on the most relevant names for their strategy.

Market Reaction and Investor Sentiment

Hyperfine shares rose in after-hours trading following the report, reflecting an earnings-per-share beat and the first-ever quarter in which revenue exceeded net cash burn. The result reinforced a narrative of improving operating leverage, as revenue grew 53% sequentially while operating expenses rose less than 2%. Still, sentiment heading into the print remained cautious: the stock had declined roughly 21% over the prior three months and more than 30% over the prior year, underscoring investor concerns about profitability and financing needs for a company that continues to report net losses.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether Hyperfine can sustain its revenue trajectory while preserving the disciplined expense structure that drove this quarter's margin expansion. The reaffirmed full-year 2026 revenue guidance of $20 million to $22 million implies continued growth in the fourth quarter, supported by new and follow-on health system orders and the international rollout of the next-generation Model 2 scanner.

Regulatory and clinical milestones remain important catalysts. Hyperfine completed enrollment in its Contrast PMR study and has said it remains on track to submit a 510(k) application to the FDA (Food and Drug Administration) by the end of 2026, a step that could broaden the clinical utility of the Swoop system. Recent CE and UKCA marking approvals also support expansion across Europe and the U.K.

Key factors to monitor include unit sales and average selling prices, gross margin durability, the pace of cash burn, and the company's cash runway. Because Hyperfine has stated it expects to require additional financing in the future, investors will also keep a close eye on the balance sheet and any capital-raising activity. As always, execution on both commercial scale and expense discipline will determine whether the current momentum translates into a clearer path toward profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations